# Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

> **NCT01405560** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 42 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Vaniprevir
- **BIOLOGICAL:** peg-IFN
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01405560
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-02
- **Primary completion:** 2013-03-29
- **Final completion:** 2013-03-29
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2018-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405560, "Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01405560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*